July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Patient Preferences for Anti-VEGF Treatment Regimens for Wet Age-Related Macular Degeneration in Japan
Author Affiliations & Notes
  • Yuji Oshima
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka, Japan
  • Takeshi Joko
    Department of Ophthalmology, Ehime University School of Medicine, Matsuyama, Ehime, Japan
  • Yoshimi Nagai
    Department of Ophthalmology, Kansai Medical University, Hirakata, Osaka, Japan
  • Ryusaburo Mori
    Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Chiyoda-ku, Tokyo, Japan
  • Koji Tanaka
    Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Chiyoda-ku, Tokyo, Japan
  • Yusuke Hikichi
    Department of Market Access, Bayer Yakuhin, Ltd, Chiyoda-ku, Tokyo, Japan
  • Tetsushi Komori
    Department of Research & Product Development, Bayer Yakuhin, Ltd, Kita-ku, Osaka, Japan
  • Joao Carrasco
    Department of Market Access, Bayer Consumer Care AG, Basel, Canton of Basel-Stadt, Switzerland
  • Martine Maculaitis
    Department of Health Outcomes Research, Kantar Health, LLC, New York, United States
  • Oliver Will
    Department of Health Outcomes Research, Kantar Health, LLC, New York, United States
  • Kathleen Beusterien
    Department of Health Outcomes Research, Kantar Health, LLC, New York, United States
  • Kanji Takahashi
    Department of Ophthalmology, Kansai Medical University, Hirakata, Osaka, Japan
  • Footnotes
    Commercial Relationships   Yuji Oshima, Alcon (F), Bayer (F); Takeshi Joko, Bayer (F); Yoshimi Nagai, Alcon (R), Bayer (R), JFC Sales Plan (R), Kowa (R), Santen (R), Senju (R); Ryusaburo Mori, Alcon (R), Bayer (R), JFC Sales Plan (R), Pfizer (R), Saten (R), Senju (R); Koji Tanaka, Alcon (R), Bayer (R), Novartis (R), Santen (R); Yusuke Hikichi, Bayer (E); Tetsushi Komori, Bayer (E); Joao Carrasco, Bayer (E); Martine Maculaitis, Bayer (C), Kantar Health (E); Oliver Will, Bayer (C), Kantar Health (E); Kathleen Beusterien, Bayer (C), Kantar Health (E); Kanji Takahashi, Alcon (F), Alcon (R), AMO (F), Bayer (R), Cark Zeiss (R), Hoya (F), Novartis (R), Otsuka (R), Pfizer (F), Pfizer (R), Santen (F), Santen (R), Senju (F), Sun Contact Lens (F)
  • Footnotes
    Support  Funded by Bayer Yakuhin, Ltd
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 93. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yuji Oshima, Takeshi Joko, Yoshimi Nagai, Ryusaburo Mori, Koji Tanaka, Yusuke Hikichi, Tetsushi Komori, Joao Carrasco, Martine Maculaitis, Oliver Will, Kathleen Beusterien, Kanji Takahashi; Patient Preferences for Anti-VEGF Treatment Regimens for Wet Age-Related Macular Degeneration in Japan. Invest. Ophthalmol. Vis. Sci. 2019;60(9):93.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To quantify preferences for different anti-vascular endothelial growth factor (anti-VEGF) treatment profiles among patients with wet age-related macular degeneration (wAMD).

Methods : Patients with a best corrected visual acuity (BCVA) in their better-seeing eye of at least a decimal notation of 0.5 (approximately 20/40 at Snellen equivalent) participated in a face-to-face cross-sectional survey across 4 university hospitals in Japan between November 2017 and June 2018. The survey included explanations of pro re nata (PRN), every two months (q8), and treat-and-extend (TAE) treatment strategies using a standardized script and a discrete choice experiment (DCE) in which patients were asked to review two different treatment profiles side-by-side and choose their preferred option. The different profiles were defined based on 4 attributes: 1-year number of injections, 1-year physician consults, chance of 1-year visual acuity (VA) improving, and chance of 2-year VA maintenance of improvement. A Hierarchical Bayes model was applied to estimate preference weights for each level of the regimen attributes.

Results : A total of 120 patients with wAMD with a mean age of 76 ± 8.0 years (female: 41%) completed the survey. Thirty patients were anti-VEGF naïve and ninety patients were anti-VEGF experienced. Of the anti-VEGF experienced patients, approximately 71% were treated with PRN. Patients were willing to accept an increase from 3 to approximately 8 injections in the first year to increase the chance of 1-year VA improvement from 25% to 40%; however, they would be willing to accept 11 injections if the chance of 2-year VA maintenance increased from 80% to 96%. The most valued attribute was 2-year VA maintenance (34%), followed by reducing the number of injections (31%). These factors were about twice as important as decreasing physician consults and increasing the chance of VA improvement (P < 0.001). When comparing different regimen profiles (TAE, q8, and PRN) based on their attributes, TAE was generally more favored by patients primarily because of its high chance of 2-year VA maintenance.

Conclusions : Informing patients with wAMD about the likelihood of long-term VA maintenance when selecting treatment is likely to increase the chance of accepting an optimal treatment regimen and number of injections.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×